Critical Contrast: Invivyd (NASDAQ:IVVD) vs. Adverum Biotechnologies (NASDAQ:ADVM)

Adverum Biotechnologies (NASDAQ:ADVM) and Invivyd (NASDAQ:IVVD) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends and valuation.

Profitability

This table compares Adverum Biotechnologies and Invivyd’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Adverum Biotechnologies	N/A	-65.14%	-40.52%
Invivyd	N/A	-155.33%	-114.88%

Volatility and Risk

Adverum Biotechnologies has a beta of 1.14, meaning that its share price is 14% more volatile than the S&P 500. Comparatively, Invivyd has a beta of 0.07, meaning that its share price is 93% less volatile than the S&P 500.

Insider & Institutional Ownership

48.2% of Adverum Biotechnologies shares are owned by institutional investors. Comparatively, 70.4% of Invivyd shares are owned by institutional investors. 4.2% of Adverum Biotechnologies shares are owned by company insiders. Comparatively, 17.9% of Invivyd shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Adverum Biotechnologies and Invivyd”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adverum Biotechnologies	$1.00 million	93.61	-$117.17 million	($5.99)	-0.75
Invivyd	$11.56 million	8.40	-$198.64 million	($1.96)	-0.41

Adverum Biotechnologies has higher earnings, but lower revenue than Invivyd. Adverum Biotechnologies is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings for Adverum Biotechnologies and Invivyd, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adverum Biotechnologies	0	1	5	0	2.83
Invivyd	0	0	4	1	3.20

Adverum Biotechnologies presently has a consensus target price of $27.83, indicating a potential upside of 518.52%. Invivyd has a consensus target price of $7.89, indicating a potential upside of 871.25%. Given Invivyd’s stronger consensus rating and higher possible upside, analysts clearly believe Invivyd is more favorable than Adverum Biotechnologies.

Summary

Invivyd beats Adverum Biotechnologies on 8 of the 14 factors compared between the two stocks.

About Adverum Biotechnologies

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

About Invivyd

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.